Characterization of the Inhibition of Hepatitis C Virus RNA Replication by Nonnucleosides

Journal of Virology

Volumn 78, Issue 2, 2004, Pages 938-946

  Tomei, Licia ^a   Altamura, Sergio ^a   Bartholomew, Linda ^a   Bisbocci, Monica ^a   Bailey, Carolyn ^b   Bosserman, Michele ^b   Cellucci, Antonella ^a   Forte, Eleonora ^a   Incitti, Ilario ^a   Orsatti, Laura ^a   Koch, Uwe ^a   De Francesco, Raffaele ^a   Olsen, David B ^b   Carroll, Steven S ^b   Migliaccio, Giovanni ^a  

^a IRBM   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BUTYL 3 (1,1 DIOXIDO 2H 1,2,4 BENZOTHIADIAZIN 3 YL) 4 HYDROXYQUINOLIN 2(1H) ONE; 2 [4 [[4' CHLORO 4 [(4 HYDROXYPIPERIDIN 1 YL)CARBONYL] 1,1' BIPHENYL 2 YL]METHOXY] 2 FLUOROPHENYL] 1 CYCLOHEXYL 1H BENZIMIDAZOLE 5 CARBOXYLIC ACID; 3 (1,1 DIOXIDO 2H 1,2,4 BENZOTHIADIAZIN 3 YL) 4 HYDROXY 1 ISOBUTYLQUINOLIN 2(1H) ONE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; N [[1 CYCLOHEXYL 2 (3 FURYL) 1H BENZIMIDAZOL 5 YL]CARBONYL] 5 HYDROXYTRYPTOPHAN; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; BINDING SITE; CLONE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME INHIBITION; GENE MAPPING; GENE MUTATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; BENZOTHIADIAZINES; BINDING SITES; CELL LINE; DRUG SYNERGISM; ENZYME INHIBITORS; HEPACIVIRUS; HUMANS; MODELS, MOLECULAR; RNA REPLICASE; RNA, VIRAL; VIRUS REPLICATION;

EID: 9144259740     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.2.938-946.2004     Document Type: Article

References (41)

1. Adachi, T., H. Ago, N. Habuka, K. Okuda, M. Komatsu, S. Ikeda, and K. Yatsunami. 2002. The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. Biochim. Biophys. Acta 1601:38-48.
2. Ago, H., T. Adachi, A. Yoshida, M. Yamamoto, N. Habuka, K. Yatsunami, and M. Miyano. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Struct. Fold Des. 7:1417-1426.
3. Beaulieu, P. L., G. Fazal, J. Gillard, G. Kukolj, and V. Austel. January 2002. Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors. WO patent 0204425.
4. Beaulieu, P. L., G. Fazal, S. Goulet, G. Kukolj, M. Poirie-, and Y. S. Tsantrizos. January 2003. Preparation of benzimidazoles as viral polymerase inhibitors. WO patent 0307945.
5. Behrens, S. E., L. Tomei, and R. De Francesco. 1996. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
6. Bressanelli, S., L. Tomei, F. A. Rey, and R. De Francesco. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76:3482-3492.
7. Bressanelli, S., L. Tomei, A. Roussel, I. Incitti, R. L. Vitale, M. Mathieu, R. De Francesco, and F. A. Rey. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. USA 96:13034-13039.
8. Carroll, S. S., V. Sardana, Z. Yang, A. R. Jacobs, C. Mizenko, D. Hall, L. Hill, J. Zugay-Murphy, and L. C. Kuo. 2000. Only a small fraction of purified hepatitis C RNA-dependent RNA polymerase is catalytically competent: implications for viral replication and in vitro assays. Biochemistry 39:8243-8249.
9. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
10. Cheney, I. W., S. Naim, V. C. Lai, S. Dempsey, D. Bellows, M. P. Walker, J. H. Shim, N. Horscroft, Z. Hong, and W. Zhong. 2002. Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virology 297:298-306.
11. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
12. De Francesco, R., and C. M. Rice. 2003. New therapies on the horizon for hepatitis C: are we close? Clin. Liver Dis. 7:211-242.
13. De Francesco, R., L. Tomei, S. Altamura, V. Summa, and G. Migliaccio. 2003. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antivir. Res. 58:1-16.
14. Dhanak, D., K. J. Duffy, V. K. Johnston, J. Lin-Goerke, M. Darcy, A. N. Shaw, B. Gu, C. Silverman, A. T. Gates, M. R. Nonnemacher, D. L. Earnshaw, D. J. Casper, A. Kaura, A. Baker, C. Greenwood, L. L. Gutshall, D. Maley, A. DelVecchio, R. Macarron, G. A. Hofmann, Z. Alnoah, H. Y. Cheng, G. Chan, S. Khandekar, R. M. Keenan, and R. T. Sarisky. 2002. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277:38322-38327.
15. Dhanak, D., A. C. Kaura, and A. Shaw. November 2001. Preparation of 3-(1,1-dioxo-2H-benzo-1,2,4-thiadiazin-3-yl)-2-quinolones as novel anti-infectives. WO patent 0185172.
16. Di Bisceglie, A. M., and J. H. Hoofnagle. 2002. Optimal therapy of hepatitis C. Hepatology 36:S121-S127.
17. Ferrari, E., J. Wright-Minogue, J. W. Fang, B. M. Baroudy, J. Y. Lau, and Z. Hong. 1999. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 73:1649-1654.
18. Gu, B., V. K. Johnston, L. L. Gutshall, T. T. Nguyen, R. R. Gontarek, M. G. Darcy, R. Tedesco, D. Dhanak, K. J. Duffy, C. C. Kao, and R. T. Sarisky. 2003. Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J. Biol. Chem. 278:16602-16607.
19. Guo, J. T., V. V. Bichko, and C. Seeger. 2001. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:8516-8523.
20. Hashimoto, H., K. Mizutani, and A. Yoshida. January 2003. Fused cyclic compounds and medicinal use thereof. WO patent 0300254.
21. Hashimoto, H., K. Mizutani, and A. Yoshida. July 2001. Preparation of heterocyclic compounds as remedies for hepatitis C. WO patent 0147883.
22. Hashimoto, H., K. Mizutani, and A. Yoshida. March 2003. Preparation of substituted 1-cyclohexyl-2-phenylhenzimidazole-5-carboxylic acids as remedies for hepatitis C. U.S. patent 2,003,050,320.
23. Hong, Z., C. E. Cameron, M. P. Walker, C. Castro, N. Yao, J. Y. Lau, and W. Zhong. 2001. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 285:6-11.
24. Lesburg, C. A., M. B. Cable, E. Ferrari, Z. Hong, A. F. Mannarino, and P. C. Weber. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943.
25. Lohmann, V., F. Korner, U. Herian, and R. Bartenschlager. 1997. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J. Virol. 71:8416-8428.
26. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
27. Love, R. A., H. E. Parge, X. Yu, M. J. Hickey, W. Diehl, J. Gao, H. Wriggers, A. Ekker, L. Wang, J. A. Thomson, P. S. Dragovich, and S. A. Fuhrman. 2003. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77:7575-7581.
28. Love, R. A., X. Yu, W. Diehl, M. J. Hickey, H. E. Parge, J. Gao, and S. Fuhrman. November 2002. Crystallization properties and structure of hepatitis C virus (HCV) NS5B RNA polymerase and its mutants, and uses in drug screening. EP patent 1256628.
29. Luo, G., R. K. Hamatake, D. M. Mathis, J. Racela, K. L. Rigat, J. Lemm, and R. J. Colonno. 2000. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J. Virol. 74:851-863.
30. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. Characterization of resistance to non-obligate chain terminating ribonucleoside analogs which inhibit HCV replication in vitro. J. Biol. Chem., in press.
31. O'Farrell, D., R. Trowbridge, D. Rowlands, and J. Jager. 2003. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol. 326:1025-1035.
32. Oh, J. W., T. Ito, and M. M. Lai. 1999. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA. J. Virol. 73:7694-7702.
33. Schmidt-Mende, J., E. Bieck, T. Hugle, F. Penin, C. M. Rice, H. E. Blum, and D. Moradpour. 2001. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 276:44052-44063.
34. Tomei, L., S. Altamura, L. Bartholomew, A. Biroccio, A. Ceccacci, L. Pacini, F. Narjes, N. Gennari, M. Bisbocci, I. Incitti, L. Orsatti, S. Harper, I. Stansfield, M. Rowley, R. De Francesco, and G. Migliaccio. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77:13225-13231.
35. Tomei, L., R. L. Vitale, I. Incitti, S. Serafini, S. Altamura, A. Vitelli, and R. De Francesco. 2000. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. J. Gen. Virol. 81:759-767.
36. Trozzi, C., L. Bartholomew, A. Ceccacci, G. Biasiol, L. Pacini, S. Altamura, F. Narjes, E. Muraglia, G. Paonessa, U. Koch, R. De Francesco, C. Steinkuhler, and G. Migliaccio. 2003. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J. Virol. 77:3669-3679.
37. Walker, M. P., and Z. Hong. 2002. HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr. Opin. Pharmacol. 2:534-540.
38. Wang, M., K. K. Ng, M. M. Cherney, L. Chan, C. G. Yannopoulos, J. Bedard, N. Morin, N. Nguyen-Ba, M. H. Alaoui-Ismaili, R. C. Bethell, and M. N. James. 2003. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278:9489-9495.
39. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:1-16.
40. Yenofsky, R. L., M. Fine, and J. W. Pellow. 1990. A mutant neomycin phosphotransferase II gene reduces the resistance of transformants to antibiotic selection pressure. Proc. Natl. Acad. Sci. USA 87:3435-3439.
41. Zhong, W., A. S. Uss, E. Ferrari, J. Y. Lau, and Z. Hong. 2000. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J. Virol. 74:2017-2022.